AU5 5
Alternative Names: AU5-5; Oral FLT3 inhibitorLatest Information Update: 11 Aug 2021
At a glance
- Originator Aucentra Therapeutics
- Class Amines; Antineoplastics; Imidazoles; Pyrimidines; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 26 Jul 2021 AU5 5 is available for licensing as of 26 Jul 2021. https://www.aucentra.com/partners-investors/
- 26 Apr 2021 Preclinical trials in Haematological malignancies in Australia (PO) before April 2021 (Aucentra Therapeutics pipeline, April 2021)
- 22 Apr 2021 Aucentra Therapeutics has patent protection for its CDKs inhibiting compounds